College of Pharmacy News

The University of Texas at Austin College of Pharmacy placed in the top ten in the entire country in the percentage of match placements with 91%, compared to the national match placement average of 82%.

The Cancer Prevention and Research Institute of Texas (CPRIT) has released its grant research funding awards for the upcoming year. All three awarded research projects at The University of Texas at Austin involve College of Pharmacy faculty.

From student scholarships to national recognition awards to prestigious appointments, the UT Pharmacy community has a lot to celebrate and be proud of right now.

Dr. Diane Ginsburg has been appointed to the Provost’s Distinguished Service Academy for her excellence in mentorship and demonstrated mastery across scholarship, teaching, leadership and service.

Pharmacy schools across the country completed their 2022 Phase I and Phase II residency matches for new or upcoming graduates of their Doctor of Pharmacy (Pharm.D.) programs. The University of Texas at Austin College of Pharmacy placed in the top ten of all pharmacy schools in the nation, and number one in Texas.

The Cancer Prevention and Research Institute of Texas (CPRIT) recently awarded grants to six faculty members at UT Austin, including the Division of Chemical Biology and Medicinal Chemistry's Kevin Dalby, Ph.D. for his Targeted Therapeutic Drug Discovery and Development Program.

Nathan Pope, Pharm.D., BCACP, FACA has been named The University of Texas at Austin College of Pharmacy’s new assistant dean of experiential education and will succeed Jennifer Ridings-Myhra, M.Ed., R.Ph., who plans to work with Dr. Pope through July and August to assist in the transition. The start date for this new role is effective July 1, 2021.

Dr. Diane Ginsburg has been accepted into the Leadership Texas 2021 class by Leadership Women, Inc. She will represent The University of Texas at Austin during Leadership Texas sessions through November 2021.

It is with great sadness that we announce the passing of Edward (Ted) Mills, Ph.D., associate professor in the Division of Pharmacology and Toxicology and Bergen Brunswig Corporation Centennial Fellow.

Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.